PET/CT with the PSMA ligand is a powerful new method for the early detection of nodal metastases in patients with biochemical relapse. The purpose of this retrospective investigation was to evaluate the volume and dimensions of nodes identified by Glu-urea-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA-11) in the setting of recurrent prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
All PET/CT images were acquired 60 ± 10 min after intravenous injection of (68)Ga-PSMA-11 (mean dose 176 MBq) In 21 patients with recurrent prostate cancer and rising PSA, 49 PSMA-positive lymph nodes were identified Using semiautomated lymph node segmentation software, node volume and short-axis and long-axis dimensions were measured and compared with the maximum standardized uptake values (SUVmax) Round nodes greater than or equal to 8 mm were considered positive by morphological criteria alone The percentage of nodes identified by elevated SUVmax but not by conventional morphological criteria was determined
The mean volume of (68)Ga-PSMA-11-positive nodes was 0 5 ml (range 0 2 - 2 3 ml), and the mean short-axis diameter was 5 8 mm (range 2 4 - 13 3 mm) In 7 patients (33 3 %) with 31 PSMA-positive nodes only 11 (36 %) were morphologically positive based on diameters >8 mm on CT In the remaining 14 patients (66 7 %), 18 (37 %) of PSMA positive lymph nodes had short-axis diameters
(68)Ga-PSMA-11 PET/CT is more sensitive than CT based 3D volumetric lymph node evaluation in determining the node status of patients with recurrent prostate cancer, and is a promising method of restaging prostate cancers in this setting
European journal of nuclear medicine and molecular imaging 2015 Jul 11 [Epub ahead of print]
Frederik L Giesel, H Fiedler, M Stefanova, F Sterzing, M Rius, K Kopka, J H Moltz, A Afshar-Oromieh, P L Choyke, U Haberkorn, C Kratochwil
Department of Nuclear Medicine, INF 400, University Hospital Heidelberg, University of Heidelberg, 69120, Heidelberg, Germany